Full text is available at the source.
Abstract
The introduction of a 7.2 mg maintenance dose of semaglutide is under evaluation for its efficacy and safety in managing obesity.
- Comparative evidence is needed for long-term pharmacotherapy to address the global rise in overweight and obesity.
- The study focuses on glucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide, semaglutide, and tirzepatide.
- The incremental value of semaglutide at the 7.2 mg dose is a key point of assessment.
- Efficacy and safety outcomes of these treatments are being evaluated in the context of obesity management.
Simplified